Research on Advance directives of Amyotrophic Lateral sclerosis Patient and QOL
肌萎缩侧索硬化症患者的预先指示及生活质量研究
基本信息
- 批准号:16590417
- 负责人:
- 金额:$ 0.9万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2004
- 资助国家:日本
- 起止时间:2004 至 2005
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Research on Advance directives of Amyotrophic Lateral sclerosis Patient and QOLResult: (1)The merit (multiple answers) of Advance directives is order (18%"talks are made in order to fulfill his hope", 16% "it complies with his/her request and medical treatment is advanced", 15%"contents of self-determination are shared", 14% "that communication of his/her, family, and medical stuff becomes good", and 12% "it is not forced medical treatment which is not desired" ), in patients' reply (N=300). It is the same as that also of nurses (N=305) and doctors (N=265) reply almost. (2) Although the prevention factor (multiple answers) through which Advance directives do not spread was the order of "only a doctor may decide treatment policy", "it not having got used to self-determination", "it not being well-known to a decision content", "the form not being standardized", and there "there being no legal basis" in the patient reply, the tendency to regard as questionable what "no legal basis is" was seen in the doctor. (3) About the policy of Advance directives spread, although (multiple answers) are 11% of order "which checks renewal of contents, and rewriting" in a patient reply 24% "information is made substantial", and 18% "which promotes a notice", subsequently to 19% "which promotes a notice", the doctor attaches importance to "legal-basis" 17%. (4) Although it is the presentation method of Advance directives, in the patient reply, it is the order of "oral", a "document", "the original form of a hospital", and a "handwriting memorandum", and the document has rivaled oral mostly. Maximum is 3 times although about 30 % has answered by the patient reply that the existence of rewriting of the contents of Advance directives.
肌萎缩侧索硬化症患者的预先指导与生活质量研究(1)优点(多个答案)的预先指令是命令(18%“为了实现他的希望而进行会谈”,16%“符合他/她的要求,先进的医疗”,15%“分享自主决定的内容”,14%“他/她,家人,患者回答“不需要强迫治疗”的占12%(N=300)。护士(N=305)和医生(N=265)的回答基本相同。(2)虽然预防因素预诊指示不传播的顺序是“只有医生可以决定治疗策略”、“没有习惯自主决定”、“对决定内容不了解”、“形式不规范”、“没有法律的依据”,在这位医生身上发现了一种倾向,即认为“没有法律的依据”是值得怀疑的。(3)关于预先指示传播的政策,虽然(多个答案)是11%的命令“检查更新的内容,并重写”在一个病人的回答24%的“信息是实质性的”,和18%的“促进通知”,其次是19%的“促进通知”,医生重视“法律依据”17%。(4)虽然是预嘱的表述方式,但在患者回复中,其顺序是“口头”、“文件”、“医院原件”、“手写备忘录”,文件大多已与口头匹敌。最多为3次,尽管约有30%的患者回答存在重写Advance指令内容的情况。
项目成果
期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Michiya Ito About the importance of the counseling in the gene diagnosis of familial adenomatous polyposis
伊藤道也谈家族性腺瘤性息肉病基因诊断中咨询的重要性
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Tomoko Saeki;Hideki Ishikawa;Ayako Nasu
- 通讯作者:Ayako Nasu
New deployment about Advance directives
关于预先指示的新部署
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Ding H;Koinuma N;Ito Michiya
- 通讯作者:Ito Michiya
Cost-effectiveness analysis of preventive intervention on osteoporosis subjects with risedronate in Japan.
日本利塞膦酸钠预防骨质疏松症受试者的成本效益分析。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Ding Hansheng;Koinuma Nobuo;Ito Michiya
- 通讯作者:Ito Michiya
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ITO Michiya其他文献
ITO Michiya的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ITO Michiya', 18)}}的其他基金
Research on the diffusion of Advance directives of ALS (Amyotrophic lateral sclerosis) patients by designation as Proxy decision maker
通过指定代理决策者对 ALS(肌萎缩侧索硬化症)患者预先指示的传播进行研究
- 批准号:
16K08858 - 财政年份:2016
- 资助金额:
$ 0.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ethical and social study on the care for ALS-D (ALS with dementia) patients and thier family
关于 ALS-D(ALS 伴痴呆)患者及其家人护理的伦理和社会研究
- 批准号:
25670239 - 财政年份:2013
- 资助金额:
$ 0.9万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Socio-medical research on the effects of the legalization to discontinue life-sustaining treatment
关于停止生命维持治疗合法化影响的社会医学研究
- 批准号:
23659248 - 财政年份:2011
- 资助金额:
$ 0.9万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Research on Economical Evaluation of Genetic Testing Diagnosis of Familial Cancer
家族性癌症基因检测诊断的经济评价研究
- 批准号:
14572122 - 财政年份:2002
- 资助金额:
$ 0.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
International comparison research on euthanasia, assisted suicide, and palliative care of line withering amyotrophic lateral sclerosis (ALS)
萎缩性肌萎缩侧索硬化症(ALS)安乐死、协助自杀和姑息治疗的国际比较研究
- 批准号:
11672239 - 财政年份:1999
- 资助金额:
$ 0.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 0.9万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 0.9万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 0.9万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 0.9万 - 项目类别:
Operating Grants